Sesen Bio pulls E.U. software for Fda-turned down cancer drug

Sesen Bio, a little biotech agency whose investigational most cancers procedure as soon as seemed poised for acceptance, said Wednesday that it experienced withdrawn its software to sector the drug in Europe.

The news follows the Foods and Drug Administration’s determination to reject Sesen’s drug, named Vicineum, on Aug. 13. Very last week, STAT noted that Sesen’s scientific demo in bladder most cancers was marked by hundreds of violations, investigator misconduct, and proof of serious toxicity the company did not publicly disclose, according to hundreds of pages of inner paperwork.

Unlock this posting by subscribing to STAT+ and get pleasure from your initial 30 times absolutely free!

GET Began